BioSpace News Archive

Drug Development

Opinion: What to Expect From an Experimental Anti-Abuse Opioid Drug

Although still in early-stage testing, Ensysce Biosciences’ formulation has demonstrated the potential to address addiction problems associated with oral oxycodone.

May 25, 2023
·
3 min read
·
Jia Jie Chen
Drug Development

Apellis Drops ALS Candidate After Disappointing Phase II Results

The Massachusetts-based biopharma became the second company this week to drop its amyotrophic lateral sclerosis hopeful after it failed to elicit significant improvement compared with placebo.

May 25, 2023
·
2 min read
·
Rosemary Scott
Business

BenevolentAI Cuts Workforce, Pipeline in Strategic Realignment

The AI drug discovery company’s reorganization will include laying off around 180 employees and dropping its atopic dermatitis candidate BEN-2293 in an effort to save nearly $56 million.

May 25, 2023
·
2 min read
·
Tristan Manalac
FDA

Braeburn’s Long-Acting Brixadi Receives FDA Clearance to Treat Opioid Use Disorder

The FDA approved Braeburn Pharmaceuticals’ new buprenorphine treatment option with extended-release medication that could pave the way for greater patient compliance.

May 25, 2023
·
3 min read
·
Lisa Munger
Drug Development

Annexon Sets Sights on Phase III Geographic Atrophy Trial Despite Missing Mid-Stage Mark

The company’s candidate, ANX007, did not significantly slow lesion growth in a Phase II trial but was effective at preserving visual function in patients with a form of dry age-related macular degeneration.

May 25, 2023
·
2 min read
·
Tristan Manalac
Drug Development

Mirati’s Sitravatinib Fails in Phase III Lung Cancer Trial, Nixes Development

The investigational kinase inhibitor failed to improve overall survival in the SAPPHIRE study of patients with non-squamous non-small cell lung cancer, causing Mirati to discontinue its development.

May 25, 2023
·
2 min read
·
Tristan Manalac
Therma Bright Expands U.S. Distribution of Venowave Device to Increase Sales Under Temporary CPT(R) & HCPCS Codes

Therma Bright Inc. (TSXV: THRM) (OTCQB: TBRIF) (“Therma” or the “Company”), developer and partner in a wide-range of leading-edge, proprietary diagnostic and medical device technologies, is pleased to announce that the Company is working with its U.S distributor network

May 25, 2023
·
4 min read
Pharm Country

Bayer Presents New Data Across Oncology Portfolio at the 2023 ASCO Annual Meeting

Bayer will highlight scientific research in oncology at the 2023 American Society of Clinical Oncology Annual Meeting, taking place from June 2-6, 2023.

May 25, 2023
·
30 min read
Drug Development

Evaxion announces promising clinical Phase 1 data for its personalized cancer vaccine EVX-01

Evaxion Biotech A/S to present promising clinical data from its EVX-01 Phase 1 clinical trial in metastatic melanoma on June 3, at the 2023 ASCO annual meeting, in Chicago, Illinois.

May 25, 2023
·
4 min read
Drug Development

Alaunos Therapeutics to Present Early Data from TCR-T Library Phase 1/2 Trial at 2023 American Society of Clinical Oncology Annual Meeting

Alaunos Therapeutics, Inc. announced that the Company will present early translational data from the first three patients treated in its ongoing TCR-T Library Phase 1/2 trial at the 2023 American Society of Clinical Oncology Annual Meeting taking place June 2-6, 2023, at the McCormick Place Convention Center in Chicago.

May 25, 2023
·
7 min read